CASPOFUNGINA HIKMA 70 mg POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION

Introduction

Package Leaflet: Information for the User

Caspofungina Hikma 50 mg powder for concentrate for solution for infusion EFG

Caspofungina Hikma 70 mg powder for concentrate for solution for infusion EFG

Caspofungina

Read all of this leaflet carefully before you or your child start using this medicine because it contains important information for you.

• Keep this leaflet, you may need to read it again.
• If you have any further questions, ask your doctor, pharmacist or nurse.
• If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack and other information

1. What is Caspofungina Hikma and what is it used for
2. What you need to know before you use Caspofungina Hikma
3. How to use Caspofungina Hikma
4. Possible side effects

5 Storage of Caspofungina Hikma

1. Contents of the pack and other information

1. What is Caspofungina Hikma and what is it used for

What is Caspofungina Hikma

Caspofungina Hikma contains a medicine called caspofungina. This belongs to a group of medicines called antifungals.

What caspofungina is used for

Caspofungina is used to treat the following infections in children, adolescents and adults:

• severe fungal infections in their tissues or organs (called “invasive candidiasis”). This infection is caused by fungal cells (yeasts) called Candida. People who may get this type of infection include those who have just had an operation or those whose immune system is weakened. Fever and chills that do not respond to antibiotic treatment are the most common symptoms of this type of infection.

invasive aspergillosis

• fungal infections in the nose, sinuses or lungs (called “invasive aspergillosis”) if other antifungal treatments have not worked or have caused side effects. This infection is caused by moulds called Aspergillus.

People who may get this type of infection include those receiving chemotherapy, those who have had a transplant and those whose immune system is weakened.

• presumed fungal infections if you have a fever and a low white blood cell count that have not improved with antibiotic treatment. People at risk of getting a fungal infection include those who have just had an operation or those whose immune system is weakened.

How caspofungina works

Caspofungina makes fungal cells fragile and prevents the fungus from growing normally. This prevents the infection from spreading and allows the body's natural defences to completely get rid of the infection.

2. What you need to know before you use Caspofungina Hikma

Do not use Caspofungina Hikma

• if you are allergic to caspofungina or any of the other ingredients of this medicine (listed in section 6).

If you are not sure, talk to your doctor, pharmacist or nurse before using your medicine.

Warnings and precautions

Talk to your doctor, pharmacist or nurse before using caspofungina if:

• you are allergic to any other medicine.
• you have ever had liver problems; you may need a different dose of this medicine.
• you are already taking cyclosporin (which is used to prevent organ transplant rejection or to cause suppression of your immune system), as your doctor will probably need to do extra blood tests during your treatment.
• you have ever had any other medical problem.

If any of the above applies to you (or if you are not sure), talk to your doctor, pharmacist or nurse before using caspofungina.

Caspofungina can also cause serious skin reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

Other medicines and Caspofungina Hikma

Tell your doctor, pharmacist or nurse if you are using, have recently used or might use any other medicines. This includes medicines obtained without a prescription, including herbal medicines.

This is because caspofungina can affect how other medicines work. Other medicines can also affect how caspofungina works.

Tell your doctor, pharmacist or nurse if you are taking any of the following medicines:

• cyclosporin or tacrolimus (which are used to prevent organ transplant rejection or to cause suppression of your immune system), as your doctor will probably need to do extra blood tests during your treatment.
• certain anti-HIV medicines such as efavirenz or nevirapine.
• phenytoin or carbamazepine (which are used to treat seizures).
• dexamethasone (a steroid).
• rifampicin (an antibiotic).

If any of the above applies to you (or if you are not sure), talk to your doctor, pharmacist or nurse before using Caspofungina.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.

• Caspofungina has not been studied in pregnant women. It should only be used during pregnancy if the potential benefit justifies the potential risk to the unborn baby.
• Women using caspofungina must not breast-feed.

Driving and using machines

There is no information to suggest that caspofungina affects the ability to drive or use machines.

3. How to use Caspofungina Hikma powder for concentrate for solution for infusion

Caspofungina will always be prepared and given to you by a healthcare professional. You will be given caspofungina:

• once a day.
• by slow injection into a vein (intravenous infusion).
• over about 1 hour.

Your doctor will decide how long you should be treated with and how much Caspofungina you should be given each day. Your doctor will monitor whether the effect of the medicine is sufficient. If you weigh more than 80 kg, you may need a different dose.

Use in children and adolescents

The dose for children and adolescents may be different to the dose in adults.

If you use more Caspofungina Hikma than you should

Your doctor will decide how much caspofungina you need and for how long each day. If you are worried that you have been given too much caspofungina, tell your doctor or nurse straight away.

In case of overdose or accidental ingestion, contact your doctor or pharmacist or call the Toxicology Information Service, telephone: 91 562 04 20, indicating the medicine and the amount taken.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Tell your doctor or nurse straight away if you notice any of the following side effects – you may need urgent medical treatment:

• rash, itching, feeling of warmth, swelling of your face, lips or throat or problems breathing: you may be having a histamine reaction to the medicine.
• difficulty breathing with wheezing or worsening of a rash that you already have: you may be having an allergic reaction to the medicine.
• cough, severe breathing difficulties: if you are an adult and have invasive aspergillosis, you may experience a severe respiratory problem that could lead to respiratory failure, rash, skin peeling, mucous membrane lesions, blisters, large areas of skin peeling.

As with any prescription medicine, some side effects can be serious. Ask your doctor for more information.

Other side effects in adults include:

Common: may affect up to 1 in 10 people:

• Decrease in haemoglobin (decrease in the substance that carries oxygen in the blood), decrease in white blood cells.
• Decrease in albumin (a type of protein) in your blood, decrease in potassium or low potassium levels in the blood.
• Headache.
• Vein inflammation.
• Shortness of breath.
• Diarrhoea, nausea or vomiting.
• Changes in some laboratory blood tests (such as increased values of some liver tests).
• Itching, rash, redness of the skin or more sweating than usual.
• Pain in the joints.
• Chills, fever.
• Itching at the injection site.

Uncommon: may affect up to 1 in 100 people:

• Changes in some laboratory blood tests (including blood clotting disorders, platelets, red blood cells and white blood cells).
• Loss of appetite, increase in body fluid, imbalance of body salts, high blood sugar, low calcium levels in the blood, high calcium levels in blood, low magnesium levels in the blood, increase in the level of medicines you are taking that weaken your immune system.
• Disorientation, feeling nervous, inability to sleep.
• Feeling dizzy, decreased sensations or sensitivity (especially in the skin), agitation, feeling sleepy, change in the way things taste, tingling or numbness.
• Blurred vision, increased tears, swollen eyelid, yellow colouration of the white of the eyes.
• Feeling of fast or irregular heartbeats, fast heartbeat, irregular heartbeat, abnormal heart rhythm, heart failure.
• Flushing, hot flushes, high blood pressure, low blood pressure, redness along a vein that is very sensitive to touch.
• Tightness in the muscles around the airways that leads to wheezing or cough, rapid breathing rate, shortness of breath that wakes you up, lack of oxygen in the blood, abnormal breathing sounds, crackling sounds in the lungs, wheezing, stuffy nose, cough, sore throat.
• Abdominal pain, pain in the upper abdomen, abdominal swelling, constipation, difficulty swallowing, dry mouth, indigestion, passing gas, stomach upset, swelling due to fluid accumulation around the abdomen.
• Decrease in bile flow, increase in liver size, yellow colouration of the skin and/or the white of the eyes, liver injury caused by a medicine or a chemical, liver disorder.
• Abnormal skin tissue, generalised itching, hives, rash of varying appearance, abnormal skin, red spots, often with itching, on arms and legs and sometimes on the face and the rest of the body.
• Back pain, pain in an arm or leg, bone pain, muscle pain, muscle weakness.
• Loss of kidney function, sudden loss of kidney function.
• Pain at the catheter site, symptoms at the injection site (redness, hard lump, pain, swelling, irritation, rash, hives, fluid leak from the catheter to the tissue), vein inflammation at the injection site.
• High blood pressure and changes in some laboratory blood tests (such as kidney electrolyte tests and coagulation tests), increase in levels of medicines you are taking that weaken your immune system.
• Chest discomfort, chest pain, feeling of change in body temperature, feeling unwell, general pain, swelling of the face, swelling of the ankles, hands or feet, swelling, pain when touched.

Other side effects in children and adolescents

Very common: may affect more than 1 in 10 people:

• Fever.

Common: may affect up to 1 in 10 people:

• Headache.
• Fast heartbeat.
• Flushing, low blood pressure.
• Changes in some laboratory blood tests (increased values of some liver tests).
• Itching, rash.
• Pain at the catheter site.
• Chills.
• Changes in some laboratory blood tests.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Agency's website: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Caspofungina Hikma

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and vial (the first two numbers are the month; the next four numbers are the year). The expiry date refers to the last day of the month shown.

Store in a refrigerator (between 2°C and 8°C).

Once Caspofungina Hikma has been prepared, it should be used straight away. This is because it does not contain any ingredients to prevent the growth of bacteria. Only a trained healthcare professional who has read the complete instructions should prepare the medicine (see below “Instructions for reconstituting and diluting Caspofungina Hikma”).

If not used immediately, the solution can be stored for up to 24 hours at 25°C or less or for 48 hours when the intravenous infusion bag (bottle) is stored refrigerated (2 to 8°C) and diluted with sodium chloride 9 mg/ml (0.9%), 4.5 mg/ml (0.45%) or 2.25 mg/ml (0.225%) solution for infusion or lactated Ringer's solution. If not used immediately, the storage times and conditions before use are the responsibility of the user and normally should not exceed 24 hours between 2 and 8°C, unless the reconstitution and dilution have taken place under validated controlled aseptic conditions.

Do not use the solution if you notice signs of discolouration or particles in suspension.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Contents of the pack and other information

Composition of Caspofungina Hikma

• The active substance is caspofungina.

Caspofungina Hikma 50 mg powder for concentrate for solution for infusion EFG.

Each vial of Caspofungina Hikma contains 50 mg of caspofungina (as acetate).

Caspofungina Hikma 70 mg powder for concentrate for solution for infusion EFG.

Each vial of Caspofungina Hikma contains 70 mg of caspofungina (as acetate).

• The other ingredients are sucrose, mannitol, hydrochloric acid (for pH adjustment), sodium hydroxide (for pH adjustment), carbon dioxide (for pH adjustment) (see section 2. What you need to know before you use Caspofungina Hikma).

Appearance and packaging

Caspofungina Hikma is a compact, sterile, white to off-white powder. The reconstituted solution is clear.

Caspofungina Hikma 50 mg powder for concentrate for solution for infusion EFG

10 ml Type I glass vial with a bromobutyl stopper and a plastic cap with a red aluminium band.

Caspofungina Hikma 70 mg powder for concentrate for solution for infusion EFG.

10 ml Type I glass vial with a bromobutyl stopper and a plastic cap with an orange aluminium band.

Each pack contains one vial of powder.

Marketing authorisation holder and manufacturer

Marketing authorisation holder

Hikma Farmacêutica (Portugal), S.A.

Estrada do Rio da Mó n.º 8, 8A e 8B – Fervença

2705-906 Terrugem SNT

Portugal

Tel.: ++351 21 960 84 10

Fax: ++351 21 961 51 02

E-mail: [email protected]

Manufacturer

Pharmadox healthcare, ltd

KW20A Kordin Industrial Park, Paola

PLA 3000Malta

Galenicum Health, S.L.U.

Sant Gabriel, 50Esplugues de Llobregat 08950

Barcelona, España

SAG Manufacturing S.L.U.

Ctra. N-I, Km 36

San Agustín de Guadalix, 28750,

Madrid, España

Hikma Italia S.p.A.

Viale Certosa, 10,

27100, Pavia (PV),

Italia

You can request more information about this medicine from the local representative of the marketing authorisation holder:

Hikma España, S.L.U.

Calle Anabel Segura nº11, Edificio A, planta 1ª, oficina 2

28108 - Alcobendas, Madrid

España

Date of last revision of this leaflet:JULY 2020

This information is intended only for healthcare professionals:

Instructions for reconstituting and diluting Caspofungina Hikma:

Reconstitution of caspofungina hikma

DO NOT USE DILUENTS CONTAINING GLUCOSE, as CASPOFUNGINA is not stable in diluents containing glucose. DO NOT MIX OR INFUSE CASPOFUNGINA WITH ANY OTHER MEDICINE, as there are no data on the compatibility of CASPOFUNGINA with other substances, additives or intravenous pharmaceutical products. The infusion solution should be inspected visually for particulate matter or a change in colour.

Caspofungina hikma 50 mg powder for solution for infusion EFG

INSTRUCTIONS FOR USE IN ADULT PATIENTS(vial 50 mg)

Step 1 Reconstitution of the vials

To reconstitute the powder, bring the vial to room temperature and add 10.5 ml of water for injectable preparations aseptically. The concentration of the reconstituted vial will be 5.2 mg/ml.

The compact lyophilized powder of white to off-white color will dissolve completely. Mix gently until a clear solution is obtained. The reconstituted solutions must be inspected visually for solid particles or a change in color. The reconstituted solution can be stored for a maximum of 24 hours at a temperature equal to or below 25 °C.

Step 2 addition of reconstituted caspofungina to the patient's infusion solution

The diluents for the final infusion solution are: sodium chloride injection solution or lactated Ringer's solution. The infusion solution is prepared by adding the appropriate amount of reconstituted concentrate (as shown in the following table) aseptically to a 250 ml infusion bag or bottle. Reduced volume infusions of 100 ml can be used if medically necessary for daily doses of 50 mg or 35 mg. Do not use if the solution is turbid or has precipitated.

Vial 50 mg: PREPARATION OF THE INFUSION SOLUTION IN ADULTS

*10.5 ml should be used for the reconstitution of all vials

INSTRUCTIONS FOR USE IN PEDIATRIC PATIENTS

Calculation of body surface area (BSA) for pediatric dosing

Before preparing the infusion, calculate the body surface area (BSA) of the patient using the following formula: (Mosteller formula [1])

BSA (m2) =

Preparation of the 70 mg/m2infusion for pediatric patients >3 months (using a 50 mg vial)

1. Determine the actual loading dose to be used in the pediatric patient using the patient's BSA (as calculated above) and the following equation:

BSA (m2) X 70 mg/m2 = loading dose

The maximum loading dose on day 1 should not exceed 70 mg regardless of the dose calculated for the patient.

1. Wait for the refrigerated caspofungina vial to reach room temperature.
2. Aseptically add 10.5 ml of water for injectable preparations

• This reconstituted solution can be stored for up to 24 hours at a temperature equal to or below 25 °C

• This will result in a final concentration of caspofungina in the vial of 5.2 mg/ml.
  1. Withdraw from the vial a volume of the medication equal to the calculated loading dose (Step 1). Transfer aseptically this volume (ml) of reconstituted caspofungina to an intravenous bag or bottle containing 250 ml of sodium chloride injection solution 0.9%, 0.45%, or 0.225%, or lactated Ringer's solution. Alternatively, the volume (ml) of reconstituted caspofungina can be added to a reduced volume of sodium chloride injection solution 0.9%, 0.45%, or 0.225%, or lactated Ringer's solution, without exceeding a final concentration of 0.5 mg/ml. This infusion solution should be used within 24 hours if stored at a temperature equal to or below 25 °C or within 48 hours if stored refrigerated between 2 and 8 °C.

Preparation of the 50 mg/m

1. Determine the actual daily maintenance dose to be used in the pediatric patient using the patient's BSA (as calculated above) and the following equation:

BSA (m2) X 50 mg/m2 = daily maintenance dose

The daily maintenance dose should not exceed 70 mg regardless of the dose calculated for the patient.

1. Wait for the refrigerated caspofungina vial to reach room temperature.
2. Aseptically add 10.5 ml of water for injectable preparations.

a This reconstituted solution can be stored for up to 24 hours at a temperature equal to or below 25 °C.

b This will result in a final concentration of caspofungina in the vial of 5.2 mg/ml.

1. Withdraw from the vial a volume of the medication equal to the calculated daily maintenance dose (Step 1). Transfer aseptically this volume (ml) of reconstituted caspofungina to an intravenous bag or bottle containing 250 ml of sodium chloride injection solution 0.9%, 0.45%, or 0.225%, or lactated Ringer's solution. Alternatively, the volume (ml) of reconstituted caspofungina can be added to a reduced volume of sodium chloride injection solution 0.9%, 0.45%, or 0.225%, or lactated Ringer's solution, without exceeding a final concentration of 0.5 mg/ml. This infusion solution should be used within 24 hours if stored at a temperature equal to or below 25 °C or within 48 hours if stored refrigerated between 2 and 8 °C.

Caspofungina Hikma 70 mg powder for concentrate for solution for infusion EFG

INSTRUCTIONS FOR USE IN ADULT PATIENTS(vial 70 mg)

Step 1 Reconstitution of the vials

To reconstitute the powder, bring the vial to room temperature and add 10.5 ml of water for injectable preparations aseptically. The concentration of the reconstituted vial will be 7.2 mg/ml.

The compact lyophilized powder of white to off-white color will dissolve completely. Mix gently until a clear solution is obtained. The reconstituted solutions must be inspected visually for solid particles or a change in color. The reconstituted solution can be stored for a maximum of 24 hours at a temperature equal to or below 25 °C.

Step 2 Addition of Caspofungina reconstituted to the patient's infusion solution

The diluents for the final infusion solution are: sodium chloride injection solution or lactated Ringer's solution. The infusion solution is prepared by adding the appropriate amount of reconstituted concentrate (as shown in the following table) aseptically to a 250 ml infusion bag or bottle. Reduced volume infusions of 100 ml can be used if medically necessary for daily doses of 50 mg or 35 mg. Do not use if the solution is turbid or has precipitated.

70 mg vial: PREPARATION OF THE INFUSION SOLUTION IN ADULTS

*10.5 ml should be used for the reconstitution of all vials

** If the 70 mg vial is not available, the 70 mg dose can be prepared from two 50 mg vials.

INSTRUCTIONS FOR USE IN PEDIATRIC PATIENTS (70 mg vial)

Calculation of body surface area (BSA) for pediatric dosing

Before preparing the infusion, calculate the body surface area (BSA) of the patient using the following formula: (Mosteller formula)

BSA (m2) =

Preparation of the 70 mg/m2infusion for pediatric patients >3 months (using a 70 mg vial)

1. Determine the actual loading dose to be used in the pediatric patient using the patient's BSA (as calculated above) and the following equation:

BSA (m2) X 70 mg/m2 = loading dose

The maximum loading dose on day 1 should not exceed 70 mg regardless of the dose calculated for the patient.

1. Wait for the refrigerated caspofungina vial to reach room temperature.
2. Aseptically add 10.5 ml of water for injectable preparations

a This reconstituted solution can be stored for up to 24 hours at a temperature equal to or below 25 °C

b This will result in a final concentration of caspofungina in the vial of 7.2 mg/ml.

1. Withdraw from the vial a volume of the medication equal to the calculated loading dose (Step 1). Transfer aseptically this volume (ml) of reconstituted caspofungina to an intravenous bag or bottle containing 250 ml of sodium chloride injection solution 0.9%, 0.45%, or 0.225%, or lactated Ringer's solution. Alternatively, the volume (ml) of reconstituted caspofungina can be added to a reduced volume of sodium chloride injection solution 0.9%, 0.45%, or 0.225%, or lactated Ringer's solution, without exceeding a final concentration of 0.5 mg/ml. This infusion solution should be used within 24 hours if stored at a temperature equal to or below 25 °C or within 48 hours if stored refrigerated between 2 and 8 °C.

Preparation of the 50 mg/m

1. Determine the actual daily maintenance dose to be used in the pediatric patient using the patient's BSA (as calculated above) and the following equation:

BSA (m2) X 50 mg/m2 = daily maintenance dose

The daily maintenance dose should not exceed 70 mg regardless of the dose calculated for the patient.

1. Wait for the refrigerated caspofungina vial to reach room temperature.
2. Aseptically add 10.5 ml of water for injectable preparations.

a This reconstituted solution can be stored for up to 24 hours at a temperature equal to or below 25 °C.

b This will result in a final concentration of caspofungina in the vial of 7.2 mg/ml.

1. Withdraw from the vial a volume of the medication equal to the calculated daily maintenance dose (Step 1). Transfer aseptically this volume (ml) of reconstituted caspofungina to an intravenous bag or bottle containing 250 ml of sodium chloride injection solution 0.9%, 0.45%, or 0.225%, or lactated Ringer's solution. Alternatively, the volume (ml) of reconstituted caspofungina can be added to a reduced volume of sodium chloride injection solution 0.9%, 0.45%, or 0.225%, or lactated Ringer's solution, without exceeding a final concentration of 0.5 mg/ml. This infusion solution should be used within 24 hours if stored at a temperature equal to or below 25 °C or within 48 hours if stored refrigerated between 2 and 8 °C.

[1] Mosteller RD: Simplified Calculation of Body Surface Area. N Engl J Med1987 Oct 22;317(17): 1098 (letter)